US3159545A - Radioactive capsules - Google Patents
Radioactive capsules Download PDFInfo
- Publication number
- US3159545A US3159545A US60312A US6031260A US3159545A US 3159545 A US3159545 A US 3159545A US 60312 A US60312 A US 60312A US 6031260 A US6031260 A US 6031260A US 3159545 A US3159545 A US 3159545A
- Authority
- US
- United States
- Prior art keywords
- radioactive
- oil
- capsule
- solid
- wax
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000002285 radioactive effect Effects 0.000 title claims description 46
- 239000002775 capsule Substances 0.000 title claims description 43
- 239000003921 oil Substances 0.000 claims description 57
- 239000000203 mixture Substances 0.000 claims description 33
- 239000007787 solid Substances 0.000 claims description 31
- 239000001993 wax Substances 0.000 claims description 24
- 239000007788 liquid Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 231100000252 nontoxic Toxicity 0.000 claims description 7
- 230000003000 nontoxic effect Effects 0.000 claims description 7
- 239000012815 thermoplastic material Substances 0.000 claims description 3
- 235000019198 oils Nutrition 0.000 description 56
- 150000001875 compounds Chemical class 0.000 description 24
- 238000002844 melting Methods 0.000 description 23
- 230000008018 melting Effects 0.000 description 23
- 239000003981 vehicle Substances 0.000 description 21
- 241000219161 Theobroma Species 0.000 description 14
- 230000000694 effects Effects 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 239000007903 gelatin capsule Substances 0.000 description 9
- 239000000155 melt Substances 0.000 description 9
- 239000012177 spermaceti Substances 0.000 description 8
- 229940084106 spermaceti Drugs 0.000 description 8
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 7
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 7
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 6
- 239000012857 radioactive material Substances 0.000 description 6
- 239000000941 radioactive substance Substances 0.000 description 6
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 5
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 5
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 5
- 239000005642 Oleic acid Substances 0.000 description 5
- 238000011109 contamination Methods 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 230000036760 body temperature Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000004163 Spermaceti wax Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 235000019385 spermaceti wax Nutrition 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 2
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 230000005258 radioactive decay Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 229940035722 triiodothyronine Drugs 0.000 description 1
- 229940117972 triolein Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1262—Capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Definitions
- This invention relates to radioactive capsules and particularly to capsules wherein radioactive compounds are retained without leakage.
- An oil such as glycerol trioleate has been tagged with a radioactive material and has been used as a tool in the study of fat metabolism.
- This radioactive isotope has been commonly deposited within a capsule and has been scaled therein by the simple step of telescoping a top capsule portion over a bottom portion of reduced diameter wherein is contained the radioactive oil.
- This particular embodiment has serious disadvantages in that the oil can possibly leak from the contained capsule, thereby causing serious contamination and reduction of the radioactive energy content. The possibility of such leakage is present and likely in ordinary handling, but the disadvantage is compounded many times by the necessary presence of air freight transport.
- a still further object of this invention is to provide ca sules suitable for oral administration wherein a liquid form of a radioactive compound is incorporated in a waxlike vehicle.
- a radioactive compound is placed in a capsule with a vehicle which is a solid at below body temperatures (37 C.) and melts at higher temperatures. It has now been found that radioactive compounds can be incorporated in those vehicles commonly employed in the suppository art. Such combined vehicle and radioactive compound can then be placed in a capsule suitable for oral ingestion and retained therein as a solid state below body temperatures. This novel article of manufacture significantly decreases any contamination hazard and eliminates the leakage of the radioactive compound from within the capsule.
- the radioactive compound is mixed with a suitable wax and oil of proper proportions so that the resulting mixture is a solid at temperatures lower than 37 C., but melts at temperatures at or above this level.
- the novel pharmaceutical form is prepared by melting a suitable wax and oil, combining therein the desired radioactive compound, transferring the molten mixture into a capsule, allowing the molten mixture to cool into a solid form and, thereafter, encapsulating the capsule so that the solid vehicle and radioactive compound therein is entirely contained within the capsular walls.
- the actual volume of molten mixture which is transferred to the capsule will be determined by the degree of radioactivity desired in the final product which, in turn, is determined by the amount of activity actually in the mixture 'on the day of preparation. Since radioactive decay constantly occurs, the procedure prescribes a preliminary assay of the molten mixture containing the radioactive source and thereafter selecting an appropriate volume of said mixture in order to provide a particular range of activity in the capsule on the day of preparation. Reference to standard decay curves for the particular radioactive source incorporated will enable the practitioner to prepare capsules which will contain a desired activity at some ascertained future date of use.
- Such capsules can be handled with greater assurance of freedom from radioactive contamination and can be quickly transported by air or other means without the extraordinary handling precautions which were necessary prior hereto in order to guard against leakage.
- Air transportation is now an added advantage because the lower temperatures of air flight make the wax-like vehicle harder, therefore, providing greater resistance to the damaged effects of lowered pressure.
- the great advantages obtained in the handling of such capsules are worthwhile because the pharmaceutical form is beneficially absorbed and utilized by the human.
- the attending clinician administers such a capsule to the patient and once the capsule reaches the stomach of the patient, the capsule material is disintegrated, the solid vehicle melts and the radioactive compound is absorbed.
- the capsules comprising an element disclosed herein are composed of a non-toxic, therapeutic, water-soluble material such as gelatin, methyl cellulose, polyvinyl alcohol or other thermoplastic, water-soluble, non-toxic materials which are therapeutically acceptable.
- the vehicle for the radioactive compounds is basically composed of a solid wax generally having melting points materially in excess of 37 C. and a solid oil which is of a lower melting point, but when mixed with the foregoing waxes in proper proportions results in a solid form which melts 1 larger amount of solid oil which melts at a lower level in order to obtain the resultant solid form at temperatures lower than 37 C.
- the choice of the waxes and solid oils is within the ordinary skill of the man in the art, once he is apprised of the teachings of this invention.
- oils and Waxes which are non-toxic and compatible with the human organism. He will next compound the oil and wax in the proper proportion to obtain a solid having the melting characteristics described herein.
- Representative and useful oils are theobroma oil (cocoa butter), hydrogenated or partially hydrogenated vegetable and plant oils such as corn, palm kernel, cottonseed, peanut, saffiower, olive and other operable solid oils.
- Suitable waxes are carbowax, spermaceti, glycerol monostearate, beeswax, cetyl alcohol and other suitable low or highmelting, non-toxic, pharmaceutical waxes.
- Parts 9 theobroma oil 4 spermaceti 13 total parts spermaccti The principles of allegation are also applicable in the event more than two ingredients are intended for combination. An example would be the combination of two solid oils of differing melting points with a solid wax of still another melting point. Recourse may be made to standard pharmaceutical texts in order to ascertain the method for combining such mixtures into a final composition melting at about 37 C.
- the radioactive compounds suitable for incorporation in the combination of the present invention are those compounds which have a known use after oral administration to the human. Such uses may either be diagnostic or therapeutic.
- Radioactive compounds which have been administered orally to the human for numerous purposes are radioactive iodine, glycerol trioleate, oleic acid, triiodothyronine and others.
- the radioisotopes which have a particular utility and which are prescribed orally can be determined by current recourse to the state of this dynamic art, for the new compounds which are tagged with radioactive atoms are constantly increasing in number and in application. If a particular radioisotope has been described in the art as an orally useful agent, then such compound can be incorporated in the novel combination disclosed herein.
- radioactive forms which are particularly useful for the present embodiment are those which occur as oils,
- oils such as glycerol trioleate and oleic acid.
- These comall pounds are liquid oils and, therefore, are particularly adaptable to being incorporated directly in the oil-wax combination which comprises the solid vehicle.
- the foregoing oils have unsaturated bonds in their chains which are suitably tagged with radioactive iodine
- Other oils with double bonds can also be tagged with such radioactive isotopes, e.g., corn oil, sai'llower oil and the like.
- oils tagged with radioactive iodine can be combined in equal volumes with the solid oil-wax combination which has been compounded to melt at 37 C. as set out hereinbefore.
- the combination of an equal volume of oil with the solid vehicle compounded to melt at 37 C. does not significantly alter such melting point.
- another inert oil can be employed as a diluent such as peanut oil or other vegetable oils. It is preferred to use an equal volume of the oil alone or diluted with another oil, which is to be combined with the solid vehicle because such volumes are easy to handle, easy to calculate and do not alter the melting point of the final composition.
- the amount of oil added to the vehicle base is substantially greater than an equal volume, the resulting mixture tends not to form a firm solid melting in the desired range. Therefore, it is a preferred and well-advised practice to incorporate at least an equal volume of the vehicle base to the oil. Of course, lesser volumes of the oil will not significantly affect the desired melting point range even though the mass tends to become more firm.
- radioactive materials which are not oils can also be incorporated in the wax-like vehicle to obtain similar advantages from the invention.
- Such radioactive substances can be either a dry powder form which carries the radioactive compounds or suspensions and emulsions thereof.
- Dry crystalline and powder forms can be incorporated directly into the wax-like vehicle by a mixing step.
- a prepared vehicle base which melts at substantially 37 C., as illustrated hcreinbefore, is melted or softened by heat, and the dry radioactive form is placed therein and mixed. It is apparent that incorporating such dry forms into the present embodiments attains advantages in the subsequent handling and administration of the radioactive materials. Hazards of contamination from capsular leakage or damage are virtually eliminated while, concurrently, an elegant pharmaceutical form for oral administration is provided.
- suspensions and emulsions of radioactive carriers can be incorporated into the embodiments of the present invention.
- a practitioner may desire to employ suspensions rather than placing a waterinsoiuble material directly into the vehicle base as described hereinbefore.
- Such suspensions can be prepared by conforming with the conventional procedures provided by that art and, thereafter, mixing said suspensions with the melted vehicle base.
- Example I Ingredient: Amount Theobroma oil 4.753 gms. 8 1spermaceti 2.334 gms.
- Glycerol triole'ate 1 tagged (1-2 mc./ml.)
- the theobroma oil and spermaceti are melted on a steam bath at temperatures not exceeding 75 C.
- the glycerol trioleate is added to this mixture and thoroughly mixed.
- the combined volume of the theobroma and spermaceti is 8 ml. which results in a vehicle melting at about 37 C.
- the melting point of the final composition is not altered from 37 C.
- a volume of approximately 0.2 ml. of this melted mixture is removed by a pipette and transferred into a bottom half of a gelatin capsule while taking the conventional precautions against radiation hazards.
- the upper half of the gelatin capsule is telescoped over the bottom portion and the melted mixture within the capsule is allowed to solidify.
- the foregoing formulation provides a sufiicient amount of melted material to prepare about 80 gelatin capsules.
- the solidified mixture melts in the range of 3436 C.
- Each capsule contains an activity of about 50-100 ,uc. as calibrated to a future date of use or approximately 120 ,uC. of 1 activity as of day of preparation.
- Example II Ingredient: Amount Glycerol monostearate 4 parts 1 Theobroma oil parts Glycerol trioleate, 1 tagged 4 ml.
- Example II The procedure steps outlined in Example I are followed to prepare 40 gelatin capsules wherein each capsule contains an activity of about 50-100 [10. as calibrated to a future date of use.
- Example III Ingredient: Amount Theobroma oil 4.753 gms. ⁇ 1spermaceti 2.334 gms.
- Oleic acid 1 tagged (l-2 mc./m1.) 8 ml.
- the theobroma and spermaceti are melted and combined with the oleic acid by process steps as described in Example I.
- the combined melted mixture is placed in a syringe which is aflixed to a syringe microburet, Model SE22, manufactured by the Micro-metric Instrument Co. of Cleveland, Ohio.
- a heating tape attached to a rheostat temperature control, is wrapped around the syringe to keep the waxes and oils in a molten state.
- the syringe microburet has a manually motivated plunger arm which terminates at a position flush against the plunger arm of the syringe.
- a dial is connected to the plunger systems whereby the desired volume of expelled molten solids can be determined. Volumes of approximately 0.2 ml. of expelled into each of the bottom portions of the gelatin capsules.
- the opening of the top portion of the gelatin capsule is dipped in an alcoholic solution of polyvinylpyrrolidone and then telescoped over the bottom portion of the capsule containing the melted composition.
- the alcoholic solution of polyvinylpyrrolidone serves to seal the capsule portions.
- the foregoing formulation provides a suflicient amount of melted mate- 6 rial to prepare about gelatin capsules.
- the solidified mixture melts in the range of 3234 C.
- Each capsule contains an activity of about 50-100 ,uC. as calibrated to a future date of use.
- An article of manufacture comprising a pharmaceutical capsule formed of a non-toxic, water-soluble, thermoplastic material and a radioactive composition compounded from pharmaceutical oils and waxes within said capsule, said radioactive composition being a liquid at about 37 C. and remaining a solid at lower temperatures.
- An article of manufacture comprising a pharmaceutical capsule formed of a non-toxic, Water-soluble thermoplastic material containing therein a radioactive composition compounded from pharmaceutical oils and waxes, said composition containing a radioactive material that is liquid, said radioactive composition melting at about normal body temperatures and remaining substantially a solid at lower temperatures.
- composition melting at body temperature is mixed with no more than an equal volume of Oil labeled with radioisotopes.
- An article of manufacture according to claim 2 wherein the capsule is made of gelatin and the radioactive composition is compounded from theobroma oil and spermaceti wax.
- said capsule is essentially composed of gelatin and said composition comprises theobroma oil, spermaceti wax and radioactive oleic acid.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Dispersion Chemistry (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NL269886D NL269886A (enrdf_load_stackoverflow) | 1960-10-04 | ||
US60312A US3159545A (en) | 1960-10-04 | 1960-10-04 | Radioactive capsules |
GB33882/61A GB938828A (en) | 1960-10-04 | 1961-09-21 | Improvements in or relating to pharmaceutical capsules comprising radioactive materials |
BE608721A BE608721A (fr) | 1960-10-04 | 1961-10-02 | Capsules radioactives |
FR883228A FR1712M (fr) | 1960-10-04 | 1961-12-28 | Capsules radioactives. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60312A US3159545A (en) | 1960-10-04 | 1960-10-04 | Radioactive capsules |
Publications (1)
Publication Number | Publication Date |
---|---|
US3159545A true US3159545A (en) | 1964-12-01 |
Family
ID=22028701
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US60312A Expired - Lifetime US3159545A (en) | 1960-10-04 | 1960-10-04 | Radioactive capsules |
Country Status (5)
Country | Link |
---|---|
US (1) | US3159545A (enrdf_load_stackoverflow) |
BE (1) | BE608721A (enrdf_load_stackoverflow) |
FR (1) | FR1712M (enrdf_load_stackoverflow) |
GB (1) | GB938828A (enrdf_load_stackoverflow) |
NL (1) | NL269886A (enrdf_load_stackoverflow) |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3421282A (en) * | 1963-09-28 | 1969-01-14 | Daiichi Kagaku Yakuhin Co Ltd | Method for obtaining capsules having oily drugs closed therein |
US3474777A (en) * | 1966-02-10 | 1969-10-28 | Amp Inc | Method of administering therapeutic agents |
US3670065A (en) * | 1968-06-19 | 1972-06-13 | Karl Gunnar Eriksson | Process for producing dosage units of a type resembling tablets |
FR2480124A1 (fr) * | 1980-04-14 | 1981-10-16 | Squibb & Sons Inc | Capsules de diagnostic et therapeutiques et procede pour les fabriquer |
US4331654A (en) * | 1980-06-13 | 1982-05-25 | Eli Lilly And Company | Magnetically-localizable, biodegradable lipid microspheres |
EP0060434A3 (en) * | 1981-03-13 | 1984-03-07 | Akademie Der Wissenschaften Der Ddr | Process for the preparation of a diagnostic or therapeutic composition containing iodine 131 |
US4505888A (en) * | 1983-05-27 | 1985-03-19 | E. I. Du Pont De Nemours & Company | Tracer for circulation determinations |
US4610868A (en) * | 1984-03-20 | 1986-09-09 | The Liposome Company, Inc. | Lipid matrix carriers for use in drug delivery systems |
US4663148A (en) * | 1984-03-21 | 1987-05-05 | Alza Corporation | Dispenser comprising telescopically engaging members |
US4663149A (en) * | 1984-03-21 | 1987-05-05 | Alza Corporation | Dispenser comprising inner and outer walls functioning as cooperative unit |
US4692326A (en) * | 1984-03-21 | 1987-09-08 | Alza Corporation | Dispenser comprising inner positioned soft or hard capsule |
US4716031A (en) * | 1984-03-21 | 1987-12-29 | Alza Corporation | Drug dispenser comprising a multiplicity of members acting together for successfully dispensing drug |
US5188837A (en) * | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
US5221535A (en) * | 1989-11-13 | 1993-06-22 | Nova Pharmaceutical Corporation | Sustained release formulations of insect repellent |
US5227165A (en) * | 1989-11-13 | 1993-07-13 | Nova Pharmaceutical Corporation | Liposphere delivery systems for local anesthetics |
US5314678A (en) * | 1992-01-28 | 1994-05-24 | Mallinckrodt Medical, Inc. | Sodium iodide 131 I capsules |
US5340588A (en) * | 1989-11-13 | 1994-08-23 | Nova Pharmaceutical Corporation | Liposphere carriers of vaccines |
US5514869A (en) * | 1994-02-22 | 1996-05-07 | Martin, Jr.; James A. | Method for estimating the probabilities of digestive tract doses due to the passage of a solid radioactive particle |
US5993374A (en) * | 1997-06-17 | 1999-11-30 | Radiance Medical Systems, Inc. | Microcapsules for site-specific delivery |
WO2001064421A1 (en) * | 2000-03-01 | 2001-09-07 | Pvaxx Technologies Ltd. | Method and apparatus for blowmoding capsules of polyvinylalcohol and blowmolded polyvinylalcohol capsules |
US20030201566A1 (en) * | 1996-12-18 | 2003-10-30 | Stevens Henry Guy | Polymer processing method and tablet-forming apparatus |
US7026375B1 (en) | 1998-08-26 | 2006-04-11 | Pvaxx Research And Development Limited | PVA-containing compositions |
US20060157054A1 (en) * | 2005-01-11 | 2006-07-20 | Boehringer Lngelheim Pharma Gmbh & Co. Kg | Two-part capsule with pre-closure for housing pharmaceutical preparations for powder inhalers |
US20080160076A1 (en) * | 1998-08-05 | 2008-07-03 | Dieter Hochrainer | Two-part capsule to accept pharmaceutical preparations for powder inhalers |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE29474E (en) * | 1966-06-02 | 1977-11-15 | Pharmacia Ab | Method for the determination of proteins and polypeptides |
GB1572226A (en) * | 1977-11-03 | 1980-07-30 | Hoechst Uk Ltd | Pharmaceutical preparations in solid unit dosage form |
FR2622110A1 (fr) * | 1987-10-26 | 1989-04-28 | Marty Georges | Pile prevue pour l'utilisation du pouvoir radio-actif des plantes a des fins medicales |
ITRM980488A1 (it) * | 1998-07-23 | 2000-01-23 | Nyl Service S R L | Capsule autosigillanti e procedimento per la loro produzione |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2780355A (en) * | 1953-11-09 | 1957-02-05 | Scherer Corp R P | Gelatin capsule containing water soluble substances |
US2830010A (en) * | 1956-05-14 | 1958-04-08 | American Cyanamid Co | Powder-filled hexylresorcinol capsules |
US2911338A (en) * | 1954-03-09 | 1959-11-03 | Abbott Lab | Capsules and method of producing |
US2956926A (en) * | 1958-09-23 | 1960-10-18 | American Cyanamid Co | Coated citric acid particles |
US2969331A (en) * | 1958-06-04 | 1961-01-24 | Ncr Co | Process of making dual-walled oil containing capsules |
US2973301A (en) * | 1959-03-12 | 1961-02-28 | Lloyd Brothers Inc | Soft gelatin capsule |
-
0
- NL NL269886D patent/NL269886A/xx unknown
-
1960
- 1960-10-04 US US60312A patent/US3159545A/en not_active Expired - Lifetime
-
1961
- 1961-09-21 GB GB33882/61A patent/GB938828A/en not_active Expired
- 1961-10-02 BE BE608721A patent/BE608721A/fr unknown
- 1961-12-28 FR FR883228A patent/FR1712M/fr active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2780355A (en) * | 1953-11-09 | 1957-02-05 | Scherer Corp R P | Gelatin capsule containing water soluble substances |
US2911338A (en) * | 1954-03-09 | 1959-11-03 | Abbott Lab | Capsules and method of producing |
US2830010A (en) * | 1956-05-14 | 1958-04-08 | American Cyanamid Co | Powder-filled hexylresorcinol capsules |
US2969331A (en) * | 1958-06-04 | 1961-01-24 | Ncr Co | Process of making dual-walled oil containing capsules |
US2956926A (en) * | 1958-09-23 | 1960-10-18 | American Cyanamid Co | Coated citric acid particles |
US2973301A (en) * | 1959-03-12 | 1961-02-28 | Lloyd Brothers Inc | Soft gelatin capsule |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3421282A (en) * | 1963-09-28 | 1969-01-14 | Daiichi Kagaku Yakuhin Co Ltd | Method for obtaining capsules having oily drugs closed therein |
US3474777A (en) * | 1966-02-10 | 1969-10-28 | Amp Inc | Method of administering therapeutic agents |
US3670065A (en) * | 1968-06-19 | 1972-06-13 | Karl Gunnar Eriksson | Process for producing dosage units of a type resembling tablets |
FR2480124A1 (fr) * | 1980-04-14 | 1981-10-16 | Squibb & Sons Inc | Capsules de diagnostic et therapeutiques et procede pour les fabriquer |
US4331654A (en) * | 1980-06-13 | 1982-05-25 | Eli Lilly And Company | Magnetically-localizable, biodegradable lipid microspheres |
EP0060434A3 (en) * | 1981-03-13 | 1984-03-07 | Akademie Der Wissenschaften Der Ddr | Process for the preparation of a diagnostic or therapeutic composition containing iodine 131 |
US4505888A (en) * | 1983-05-27 | 1985-03-19 | E. I. Du Pont De Nemours & Company | Tracer for circulation determinations |
US4610868A (en) * | 1984-03-20 | 1986-09-09 | The Liposome Company, Inc. | Lipid matrix carriers for use in drug delivery systems |
US4663148A (en) * | 1984-03-21 | 1987-05-05 | Alza Corporation | Dispenser comprising telescopically engaging members |
US4663149A (en) * | 1984-03-21 | 1987-05-05 | Alza Corporation | Dispenser comprising inner and outer walls functioning as cooperative unit |
US4692326A (en) * | 1984-03-21 | 1987-09-08 | Alza Corporation | Dispenser comprising inner positioned soft or hard capsule |
US4716031A (en) * | 1984-03-21 | 1987-12-29 | Alza Corporation | Drug dispenser comprising a multiplicity of members acting together for successfully dispensing drug |
US5227165A (en) * | 1989-11-13 | 1993-07-13 | Nova Pharmaceutical Corporation | Liposphere delivery systems for local anesthetics |
US5221535A (en) * | 1989-11-13 | 1993-06-22 | Nova Pharmaceutical Corporation | Sustained release formulations of insect repellent |
US5188837A (en) * | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
US5340588A (en) * | 1989-11-13 | 1994-08-23 | Nova Pharmaceutical Corporation | Liposphere carriers of vaccines |
US5314678A (en) * | 1992-01-28 | 1994-05-24 | Mallinckrodt Medical, Inc. | Sodium iodide 131 I capsules |
US5514869A (en) * | 1994-02-22 | 1996-05-07 | Martin, Jr.; James A. | Method for estimating the probabilities of digestive tract doses due to the passage of a solid radioactive particle |
US20030201566A1 (en) * | 1996-12-18 | 2003-10-30 | Stevens Henry Guy | Polymer processing method and tablet-forming apparatus |
US5993374A (en) * | 1997-06-17 | 1999-11-30 | Radiance Medical Systems, Inc. | Microcapsules for site-specific delivery |
US20080160076A1 (en) * | 1998-08-05 | 2008-07-03 | Dieter Hochrainer | Two-part capsule to accept pharmaceutical preparations for powder inhalers |
US8298575B2 (en) | 1998-08-05 | 2012-10-30 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Two-part capsule to accept pharmaceutical preparations for powder inhalers |
US7026375B1 (en) | 1998-08-26 | 2006-04-11 | Pvaxx Research And Development Limited | PVA-containing compositions |
WO2001064421A1 (en) * | 2000-03-01 | 2001-09-07 | Pvaxx Technologies Ltd. | Method and apparatus for blowmoding capsules of polyvinylalcohol and blowmolded polyvinylalcohol capsules |
US20030152619A1 (en) * | 2000-03-01 | 2003-08-14 | Stevens Henry Guy | Method and apparatus for blowmoding capsules of polyvinylalcohol and blowmolded polyvinylalcohol capsules |
AU2001235855B2 (en) * | 2000-03-01 | 2005-08-04 | Pvaxx Research And Development Limited | Method and apparatus for blowmoding capsules of polyvinylalcohol and blowmolded polyvinylalcohol capsules |
AU2001235855B9 (en) * | 2000-03-01 | 2006-01-12 | Pvaxx Research And Development Limited | Method and apparatus for blowmoding capsules of polyvinylalcohol and blowmolded polyvinylalcohol capsules |
US7195777B2 (en) | 2000-03-01 | 2007-03-27 | Pvaxx Research & Development Limited | Method and apparatus for blowmoding capsules of polyvinylalcohol and blowmolded polyvinylalcohol capsules |
CN1321794C (zh) * | 2000-03-01 | 2007-06-20 | Pvaxx研究和开发有限公司 | 用于吹塑聚乙烯醇胶囊的方法和装置和吹塑的聚乙烯醇胶囊 |
US20060157054A1 (en) * | 2005-01-11 | 2006-07-20 | Boehringer Lngelheim Pharma Gmbh & Co. Kg | Two-part capsule with pre-closure for housing pharmaceutical preparations for powder inhalers |
US8662076B2 (en) | 2005-01-11 | 2014-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Two-part capsule with pre-closure for housing pharmaceutical preparations for powder inhalers |
Also Published As
Publication number | Publication date |
---|---|
GB938828A (en) | 1963-10-09 |
NL269886A (enrdf_load_stackoverflow) | |
FR1712M (fr) | 1963-02-25 |
BE608721A (fr) | 1962-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3159545A (en) | Radioactive capsules | |
US3139383A (en) | Encapsulated time release pellets and method for encapsulating the same | |
CN1045884C (zh) | 含有活性剂的高剂量制剂 | |
US4002718A (en) | Gelatin-encapsulated digoxin solutions and method of preparing the same | |
US2921883A (en) | Novel coating material for medicaments | |
US4450877A (en) | Pharmaceutical preparations in solid unit dosage form | |
JPS62114911A (ja) | 経口投与型徐放性医薬製剤 | |
US6207191B1 (en) | Multi-stage drug delivery system | |
Walker et al. | The filling of molten and thixotropic formulations into hard gelatin capsules | |
US3061510A (en) | Radioactive iodinated (i131) fatty material admixed with wax-like material in capsule | |
EP0706381A1 (en) | Soft-shelled gelatin encapsulated particles | |
EP0103995B1 (en) | Medicated suppository | |
CN116942684A (zh) | 一种用于治疗脂肪性肝炎的药物组合物及其制备方法 | |
SE512412C2 (sv) | Farmaceutisk komposition i kapselform bestående av ranitidin och en icke-vattenhaltig grundmassa | |
US4761407A (en) | Solid galenical form for oral administration, and the process for its preparation | |
US3663686A (en) | Biodegradable radioactive particles | |
US3121041A (en) | Capsule containing a pharmaceutically useful radioactive material | |
DE2838387C2 (enrdf_load_stackoverflow) | ||
EP0042076B1 (en) | Process for filling hard capsules with pharmaceutical products containing phospholipids and being highly viscous at room temperature | |
US2298122A (en) | Digitalis capsule | |
US6352717B2 (en) | Process for encapsulating shear sensitive fill masses into capsules and capsules containing shear sensitive fill masses | |
US3927196A (en) | Soluble capsules | |
JPS638327A (ja) | ペレツトから構成されるモ−ルデイング | |
WO1999006031A1 (en) | Pharmaceutical formulation for camptothecin analogues in gelatin capsule | |
CN111759821B (zh) | 一种度他雄胺软胶囊药物组合物 |